🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This is long overdue! bostonglobe.com/2022/02/02/nat… via The Boston Globe

Congrats! Awesome piece!

apple.news/AH0VsaAd8QGu0L…

Raffaella Sadun on stage talking about managerial practices and the massive effort at data collection the research team has been exerting over the years

Axcella shows highly statistically improvement in physical&mental fatique in severe long covid fatique patients. We will engage regulators on a potential pivotal trial. The need is great and AXA1125 is the first to show patient reported outcomes. #longcovid #fatigue Axcella Health

At Flagship Pioneering, we typically create 6-8 bioplatform companies a year. Every company, from Tessera Therapeutics to Generate:Biomedicines and Moderna, are born of the same process of "emergent discovery." Read more: hbr.org/2021/09/what-e…

Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) | Business Wire businesswire.com/news/home/2022…

#ICYMI: Watch Noubar Afeyan at #CodeCon share how instead of discovering biologic drugs, we're computer-generating them in an attempt to bring medicines to patients faster, cheaper, and better tailored to their specific conditions. #FlagshipFounded ow.ly/WuO750L7aG9

The artisanal nature of #drugdiscovery is inherently difficult to scale. In an interview with Jonathan Smith at Labiotech.eu, our CEO Mike Nally shares how we are harnessing the power of #machinelearning and #proteinengineering to solve the industry's productivity crisis.

So well deserved. Dick is a great thinker, great teacher, and great person. He was doing innovation long before it was cool.

The last 10 yards of the supply chain is a real killer.

Flagship unveils Metaphore Biotechnologies, a company pioneering the use of machine learning and molecular mimicry to create transformative therapeutics. Read more: bit.ly/3O832lA #FlagshipFounded Metaphore Biotechnologies

Which would you prefer: Advanced treatment for Stage 4 cancer that briefly prolongs your life or an earlier intervention that stopped you from getting sick? The answer is obvious. Yet as a nation, we’ve failed to incentivize preemptive health innovation, despite the growing

Sustaining business growth is extremely challenging for companies in any industry – including #lifesciences & #healthcare. So, what’s the recipe for success? Harvard Business School Professor Gary Pisano offers his insights based on two decades of research. tinyurl.com/4ejdhw4n

hbr.org/2024/03/how-fa…

Proud of the team of never-settlers, creative thinkers, and company builders at Flagship Pioneering and our work to imagine, innovate, and accelerate scientific progress for patients and for a more sustainable planet.

In a WBUR article by Elisabeth Harrison, our CEO Mike Nally highlights our progress using AI to generate proteins not yet found in nature: "What’s really exciting is that the answers are just getting better and better.” wbur.org/news/2024/03/1…

This biotech incubator has built 100+ companies by asking, What if . . . ? fastcompany.com/91041235/flags…

Gary Pisano (Gary Pisano), Flagship Academic Partner and Harry E. Figgie Jr. Professor of Business Administration at Harvard Business School, discusses what can keep companies from growing, lessons a fast food chain and cave rescue can serve up about growth and innovation, and the

What if we could generate novel protein therapeutics using new computational tools, without having to discover them through trial and error? That’s what we at Flagship Pioneering asked ourselves in founding Generate:Biomedicines. With new, computationally-derived medicines now advancing